Ultragenyx Pharmaceutical (RARE) Cash & Current Investments (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Cash & Current Investments for 14 consecutive years, with $413.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments fell 16.46% year-over-year to $413.0 million; the TTM figure through Mar 2026 stood at $413.0 million (down 16.46% YoY), while the FY2025 annual figure was $680.0 million, up 11.48% from the prior year.
• Cash & Current Investments slipped to $413.0 million in Q1 2026 per RARE's latest filing, from $680.0 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $888.7 million in Q3 2022 and bottomed at $135.8 million in Q4 2022.
• Historically, Cash & Current Investments has averaged $524.3 million across 5 years, with a median of $542.8 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Current Investments plunged 58.37% — and 2024, when it jumped 180.84%.
• Ultragenyx Pharmaceutical's Cash & Current Investments stood at $135.8 million in 2022, then jumped by 60.0% to $217.2 million in 2023, then surged by 180.84% to $610.0 million in 2024, then rose by 11.48% to $680.0 million in 2025, then tumbled by 39.26% to $413.0 million in 2026.
• Business Quant data shows RARE's Cash & Current Investments at $413.0 million in Q1 2026, $680.0 million in Q4 2025, and $425.2 million in Q3 2025.